Share Price and Basic Stock Data
Last Updated: June 20, 2025, 9:17 pm
PEG Ratio | 2.78 |
---|
Competitors of Rossari Biotech Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
HP Adhesives Ltd | 456 Cr. | 50.1 | 108/42.6 | 25.6 | 20.0 | 0.60 % | 13.9 % | 10.1 % | 2.00 |
Haryana Leather Chemicals Ltd | 35.3 Cr. | 71.8 | 124/62.6 | 15.3 | 87.4 | 1.39 % | 8.04 % | 5.47 % | 10.0 |
Hardcastle & Waud Mfg Co Ltd | 49.8 Cr. | 732 | 1,355/600 | 38.6 | 670 | 0.00 % | 6.20 % | 2.87 % | 10.0 |
Grauer & Weil (India) Ltd | 4,363 Cr. | 96.2 | 120/78.0 | 27.8 | 20.7 | 0.52 % | 23.8 % | 18.0 % | 1.00 |
DMCC Speciality Chemicals Ltd | 640 Cr. | 258 | 453/241 | 29.7 | 91.1 | 0.39 % | 14.6 % | 9.87 % | 10.0 |
Industry Average | 13,022.56 Cr | 791.65 | 51.33 | 158.55 | 0.39% | 13.28% | 25.57% | 6.44 |
Quarterly Result
Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 439 | 435 | 425 | 389 | 406 | 411 | 483 | 464 | 473 | 490 | 498 | 513 | 580 |
Expenses | 387 | 377 | 369 | 335 | 352 | 353 | 420 | 400 | 409 | 425 | 432 | 448 | 510 |
Operating Profit | 52 | 58 | 57 | 54 | 55 | 58 | 64 | 64 | 64 | 65 | 66 | 65 | 69 |
OPM % | 12% | 13% | 13% | 14% | 13% | 14% | 13% | 14% | 13% | 13% | 13% | 13% | 12% |
Other Income | 3 | 1 | 1 | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 2 |
Interest | 5 | 5 | 8 | 5 | 4 | 6 | 5 | 4 | 3 | 4 | 4 | 5 | 6 |
Depreciation | 17 | 15 | 16 | 16 | 16 | 14 | 15 | 15 | 16 | 15 | 15 | 18 | 18 |
Profit before tax | 34 | 39 | 34 | 35 | 37 | 39 | 45 | 48 | 46 | 47 | 48 | 42 | 48 |
Tax % | 30% | 26% | 29% | 26% | 22% | 26% | 26% | 28% | 25% | 26% | 27% | 25% | 28% |
Net Profit | 24 | 29 | 24 | 26 | 29 | 29 | 33 | 34 | 34 | 35 | 35 | 32 | 34 |
EPS in Rs | 4.37 | 5.21 | 4.34 | 4.66 | 5.25 | 5.30 | 5.97 | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.22 |
Last Updated: May 31, 2025, 7:56 am
Below is a detailed analysis of the quarterly data for Rossari Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 580.00 Cr.. The value appears strong and on an upward trend. It has increased from 513.00 Cr. (Dec 2024) to 580.00 Cr., marking an increase of 67.00 Cr..
- For Expenses, as of Mar 2025, the value is 510.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 448.00 Cr. (Dec 2024) to 510.00 Cr., marking an increase of 62.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 65.00 Cr. (Dec 2024) to 69.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Mar 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 13.00% (Dec 2024) to 12.00%, marking a decrease of 1.00%.
- For Other Income, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 18.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Dec 2024) to 48.00 Cr., marking an increase of 6.00 Cr..
- For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Dec 2024) to 28.00%, marking an increase of 3.00%.
- For Net Profit, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 6.22. The value appears strong and on an upward trend. It has increased from 5.73 (Dec 2024) to 6.22, marking an increase of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 4:17 pm
Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Sales | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 |
Expenses | 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 |
Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 |
OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% |
Other Income | 1 | 4 | 9 | 13 | 6 | 8 | 5 |
Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 |
Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 |
Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 |
Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% |
Net Profit | 46 | 65 | 80 | 98 | 107 | 131 | 136 |
EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 |
Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
YoY Net Profit Growth
Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 41.30% | 23.08% | 22.50% | 9.18% | 22.43% | 3.82% |
Change in YoY Net Profit Growth (%) | 0.00% | -18.23% | -0.58% | -13.32% | 13.25% | -18.61% |
Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 12% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 12% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -8% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 13% |
Last Year: | 12% |
Last Updated: Unknown
Balance Sheet
Last Updated: June 16, 2025, 11:26 am
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 |
Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 |
Borrowings | 8 | 67 | 0 | 8 | 74 | 119 | 218 |
Other Liabilities | 118 | 118 | 152 | 442 | 375 | 401 | 482 |
Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 |
Fixed Assets | 74 | 94 | 181 | 607 | 585 | 578 | 598 |
CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 |
Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 |
Other Assets | 173 | 338 | 379 | 611 | 712 | 880 | 1,063 |
Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 |
Below is a detailed analysis of the balance sheet data for Rossari Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,174.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,037.00 Cr. (Mar 2024) to 1,174.00 Cr., marking an increase of 137.00 Cr..
- For Borrowings, as of Mar 2025, the value is 218.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 119.00 Cr. (Mar 2024) to 218.00 Cr., marking an increase of 99.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 482.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 401.00 Cr. (Mar 2024) to 482.00 Cr., marking an increase of 81.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,886.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,567.00 Cr. (Mar 2024) to 1,886.00 Cr., marking an increase of 319.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 598.00 Cr.. The value appears strong and on an upward trend. It has increased from 578.00 Cr. (Mar 2024) to 598.00 Cr., marking an increase of 20.00 Cr..
- For CWIP, as of Mar 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2024) to 140.00 Cr., marking an increase of 93.00 Cr..
- For Investments, as of Mar 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 21.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,063.00 Cr.. The value appears strong and on an upward trend. It has increased from 880.00 Cr. (Mar 2024) to 1,063.00 Cr., marking an increase of 183.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,886.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,567.00 Cr. (Mar 2024) to 1,886.00 Cr., marking an increase of 319.00 Cr..
Notably, the Reserves (1,174.00 Cr.) exceed the Borrowings (218.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Free Cash Flow | 70.00 | 38.00 | 124.00 | 176.00 | 149.00 | 131.00 | 47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|
Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 |
Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 |
Days Payable | 114 | 95 | 104 | 61 | 56 | 62 |
Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 |
Working Capital Days | 25 | 39 | 60 | 64 | 57 | 85 |
ROCE % | 38% | 29% | 24% | 18% | 18% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
SBI Small Cap Fund | 2,016,798 | 0.64 | 145.68 | 2,016,798 | 2025-04-22 14:12:24 | 0% |
UTI Flexi Cap Fund | 1,915,752 | 0.54 | 138.38 | 1,915,752 | 2025-04-22 15:56:53 | 0% |
SBI Flexi Cap Fund | 1,648,008 | 0.64 | 119.04 | 1,648,008 | 2025-04-22 15:56:53 | 0% |
Canara Robeco Small Cap Fund | 1,067,293 | 0.93 | 85.29 | 1,067,293 | 2025-04-22 15:56:53 | 0% |
UTI Small Cap Fund | 407,215 | 0.85 | 29.42 | 407,215 | 2025-04-22 15:56:53 | 0% |
Bandhan Focused Equity Fund | 228,933 | 1.23 | 18.3 | 228,933 | 2025-04-22 15:56:53 | 0% |
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan | 143,597 | 0.2 | 10.37 | 143,597 | 2025-04-22 15:56:53 | 0% |
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan | 143,597 | 0.2 | 10.37 | 143,597 | 2025-04-22 15:56:53 | 0% |
Nippon India Nifty Smallcap 250 Index Fund | 12,015 | 0.1 | 0.96 | 12,015 | 2025-04-22 15:56:54 | 0% |
SBI Tax Advantage Fund - Series III | 7,000 | 1.55 | 0.51 | 7,000 | 2025-04-22 15:56:54 | 0% |
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Basic EPS (Rs.) | 24.66 | 23.67 | 19.46 | 17.81 | 15.56 |
Diluted EPS (Rs.) | 24.63 | 23.62 | 19.38 | 17.70 | 15.47 |
Cash EPS (Rs.) | 36.57 | 34.56 | 30.68 | 26.19 | 19.73 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
Revenue From Operations / Share (Rs.) | 375.74 | 331.35 | 300.22 | 269.36 | 136.60 |
PBDIT / Share (Rs.) | 48.60 | 46.56 | 41.43 | 35.50 | 25.47 |
PBIT / Share (Rs.) | 36.49 | 35.63 | 30.02 | 26.77 | 21.07 |
PBT / Share (Rs.) | 33.27 | 32.12 | 25.97 | 24.47 | 20.49 |
Net Profit / Share (Rs.) | 24.46 | 23.62 | 19.27 | 17.46 | 15.34 |
NP After MI And SOA / Share (Rs.) | 24.63 | 23.66 | 19.45 | 17.74 | 15.45 |
PBDIT Margin (%) | 12.93 | 14.05 | 13.79 | 13.17 | 18.64 |
PBIT Margin (%) | 9.71 | 10.75 | 9.99 | 9.93 | 15.42 |
PBT Margin (%) | 8.85 | 9.69 | 8.65 | 9.08 | 15.00 |
Net Profit Margin (%) | 6.50 | 7.12 | 6.41 | 6.48 | 11.22 |
NP After MI And SOA Margin (%) | 6.55 | 7.13 | 6.47 | 6.58 | 11.30 |
Return on Networth / Equity (%) | 11.50 | 12.47 | 11.71 | 12.13 | 19.62 |
Return on Capital Employeed (%) | 14.85 | 17.15 | 16.22 | 15.31 | 26.61 |
Return On Assets (%) | 7.19 | 8.31 | 7.84 | 7.77 | 14.29 |
Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.03 | 0.00 | 0.00 |
Total Debt / Equity (X) | 0.15 | 0.10 | 0.08 | 0.01 | 0.00 |
Asset Turnover Ratio (%) | 1.20 | 1.25 | 1.26 | 1.63 | 1.37 |
Current Ratio (X) | 1.94 | 1.99 | 2.08 | 2.07 | 2.36 |
Quick Ratio (X) | 1.28 | 1.32 | 1.54 | 1.42 | 1.73 |
Inventory Turnover Ratio (X) | 4.08 | 5.22 | 5.70 | 6.80 | 5.66 |
Dividend Payout Ratio (NP) (%) | 2.02 | 2.11 | 2.56 | 2.81 | 3.16 |
Dividend Payout Ratio (CP) (%) | 1.35 | 1.44 | 1.61 | 1.88 | 2.46 |
Earning Retention Ratio (%) | 97.98 | 97.89 | 97.44 | 97.19 | 96.84 |
Cash Earning Retention Ratio (%) | 98.65 | 98.56 | 98.39 | 98.12 | 97.54 |
Interest Coverage Ratio (X) | 15.11 | 13.28 | 10.24 | 15.44 | 44.20 |
Interest Coverage Ratio (Post Tax) (X) | 8.60 | 7.74 | 5.76 | 8.60 | 27.62 |
Enterprise Value (Cr.) | 3475.13 | 3801.34 | 3233.01 | 4985.62 | 5300.00 |
EV / Net Operating Revenue (X) | 1.67 | 2.08 | 1.95 | 3.36 | 7.47 |
EV / EBITDA (X) | 12.91 | 14.78 | 14.15 | 25.51 | 40.08 |
MarketCap / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
Retention Ratios (%) | 97.97 | 97.88 | 97.43 | 97.18 | 96.83 |
Price / BV (X) | 2.82 | 3.56 | 3.59 | 6.25 | 13.18 |
Price / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
EarningsYield | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Rossari Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.67 (Mar 24) to 24.66, marking an increase of 0.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.63, marking an increase of 1.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 36.57. This value is within the healthy range. It has increased from 34.56 (Mar 24) to 36.57, marking an increase of 2.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 375.74. It has increased from 331.35 (Mar 24) to 375.74, marking an increase of 44.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.60. This value is within the healthy range. It has increased from 46.56 (Mar 24) to 48.60, marking an increase of 2.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 36.49. This value is within the healthy range. It has increased from 35.63 (Mar 24) to 36.49, marking an increase of 0.86.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.27. This value is within the healthy range. It has increased from 32.12 (Mar 24) to 33.27, marking an increase of 1.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.46. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.46, marking an increase of 0.84.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.66 (Mar 24) to 24.63, marking an increase of 0.97.
- For PBDIT Margin (%), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 14.05 (Mar 24) to 12.93, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 9.71. This value is below the healthy minimum of 10. It has decreased from 10.75 (Mar 24) to 9.71, marking a decrease of 1.04.
- For PBT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has decreased from 9.69 (Mar 24) to 8.85, marking a decrease of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 7.12 (Mar 24) to 6.50, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.55. This value is below the healthy minimum of 8. It has decreased from 7.13 (Mar 24) to 6.55, marking a decrease of 0.58.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 15. It has decreased from 12.47 (Mar 24) to 11.50, marking a decrease of 0.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has decreased from 17.15 (Mar 24) to 14.85, marking a decrease of 2.30.
- For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 8.31 (Mar 24) to 7.19, marking a decrease of 1.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.20. It has decreased from 1.25 (Mar 24) to 1.20, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.94, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.28, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.08. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 4.08, marking a decrease of 1.14.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 20. It has decreased from 2.11 (Mar 24) to 2.02, marking a decrease of 0.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 20. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Mar 25, the value is 97.98. This value exceeds the healthy maximum of 70. It has increased from 97.89 (Mar 24) to 97.98, marking an increase of 0.09.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.65. This value exceeds the healthy maximum of 70. It has increased from 98.56 (Mar 24) to 98.65, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.11. This value is within the healthy range. It has increased from 13.28 (Mar 24) to 15.11, marking an increase of 1.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 8.60, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,475.13. It has decreased from 3,801.34 (Mar 24) to 3,475.13, marking a decrease of 326.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.67, marking a decrease of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 12.91. This value is within the healthy range. It has decreased from 14.78 (Mar 24) to 12.91, marking a decrease of 1.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For Retention Ratios (%), as of Mar 25, the value is 97.97. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 97.97, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 2.82. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.82, marking a decrease of 0.74.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
- Net Profit Margin: 6.5%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.85% (Industry Average ROCE: 13.28%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.5% (Industry Average ROE: 24.77%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.2 (Industry average Stock P/E: 44.92)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.15
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.5%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Chemicals - Speciality - Others | Rossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079 | investors@rossari.com http://www.rossari.com |
Management | |
---|---|
Name | Position Held |
Mr. Edward Menezes | Executive Chairman |
Mr. Sunil Chari | Managing Director |
Mr. Aseem Dhru | Independent Director |
Ms. Aparna Sharma | Independent Director |
Ms. Esha Achan | Independent Director |
Mr. Gurudas Aras | Independent Director |
FAQ
What is the intrinsic value of Rossari Biotech Ltd?
Rossari Biotech Ltd's intrinsic value (as of 20 June 2025) is ₹568.51 — 15.15% lower the current market price of 670.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,714 Cr. market cap, FY2025-2026 high/low of ₹973/568, reserves of 1,174 Cr, and liabilities of 1,886 Cr.
What is the Market Cap of Rossari Biotech Ltd?
The Market Cap of Rossari Biotech Ltd is 3,714 Cr..
What is the current Stock Price of Rossari Biotech Ltd as on 20 June 2025?
The current stock price of Rossari Biotech Ltd as on 20 June 2025 is 670.
What is the High / Low of Rossari Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Rossari Biotech Ltd stocks is ₹973/568.
What is the Stock P/E of Rossari Biotech Ltd?
The Stock P/E of Rossari Biotech Ltd is 27.2.
What is the Book Value of Rossari Biotech Ltd?
The Book Value of Rossari Biotech Ltd is 214.
What is the Dividend Yield of Rossari Biotech Ltd?
The Dividend Yield of Rossari Biotech Ltd is 0.07 %.
What is the ROCE of Rossari Biotech Ltd?
The ROCE of Rossari Biotech Ltd is 15.8 %.
What is the ROE of Rossari Biotech Ltd?
The ROE of Rossari Biotech Ltd is 12.2 %.
What is the Face Value of Rossari Biotech Ltd?
The Face Value of Rossari Biotech Ltd is 2.00.